Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM
| Authors |
Anna-Karin Elf Peter Bernhardt Tobias Hofving Yvonne Arvidsson Eva Forssell-Aronsson Bo Wängberg Ola Nilsson Viktor Johanson |
|---|---|
| Published in | Journal of Nuclear Medicine |
| Volume | 58 |
| Issue | 2 |
| Pages | 288-292 |
| ISSN | 0161-5505 |
| Publication year | 2017 |
| Published at |
Institute of Clinical Sciences, Department of Radiation Physics Institute of Clinical Sciences, Department of Surgery Sahlgrenska Cancer Center Institute of Biomedicine, Department of Pathology |
| Pages | 288-292 |
| Language | en |
| Links |
dx.doi.org/10.2967/jnumed.116.17758... www.ncbi.nlm.nih.gov/entrez/query.f... |
| Subject categories | Cancer and Oncology |
Neuroendocrine tumors (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled somatostatin analogs. However, the efficacy of such treatment is low and needs to be optimized.To evaluate the potential radiosensitizing effects of NAMPT inhibition on (177)Lu-DOTATATE treatment in a NET model.Nude mice xenografted with the human NET cell line GOT1 were treated with semi-efficient doses of (177)Lu-DOTATATE (7,5 MBq, i.v.) and/or GMX1778 (100 mg/kg/week, p.o.).Median time to tumor progression (tumor volume larger than at day 0) was 3 days for controls, 7 days for single dose GMX1778, 28 days for single dose (177)Lu-DOTATATE and 35 days for 3 weekly doses of GMX1778. Combined treatment with (177)Lu-DOTATATE and GMX1778 x1 resulted in a median time to progression of 98 days. After (177)Lu-DOTATATE and 3 weekly doses of GMX1778 none of the tumors progressed within 120 days.The NAMPT inhibitor GMX1778 enhances the efficacy of (177)Lu-DOTATATE treatment and induces a prolonged antitumor response. Combinations of radiolabeled somatostatin analogs and radiosensitizing drugs should be further evaluated to optimize the efficacy of peptide receptor radionuclide therapy in NETs.
© UNIVERSITY OF GOTHENBURG • Sweden • Box 100 • SE-405 30 Gothenburg
Phone: +46 31 786 0000 • Contact • Organisation number: 202100-3153
About the website
Facebook
Twitter
Instagram
Youtube
Weibo